#South Korea #Seoul #Lunit #AI Diagnostics #Agilent Technologies

Lunit and Agilent Technologies Announce Strategic Collaboration

In a groundbreaking initiative, Lunit, a frontrunner in AI-based cancer diagnostics, and Agilent Technologies, a powerhouse in life sciences and diagnostics, have unveiled a strategic collaboration aimed at revolutionizing companion diagnostic solutions. This partnership was announced on September 22, 2025, and is poised to make significant strides in the field of precision medicine.

Lunit, known for its cutting-edge AI algorithms, will combine its expertise with Agilent's renowned capabilities in tissue-based diagnostics. This collaboration aims to address the growing demand for advanced biomarker assays necessary for the development of new pharmacological therapies. The duo intends to create tools that will enhance both the accuracy of diagnoses and the measurement of therapeutic efficacy, thus paving the way for more personalized treatment options for patients.

The agreement highlights the initial focus on leveraging Lunit's AI technology in conjunction with Agilent's state-of-the-art assays. By focusing on biomarker evaluation, this collaboration is designed to support pharmaceutical companies in the development of companion diagnostic products. This is particularly vital as the landscape of cancer treatment shifts towards personalized approaches that hinge on accurate biomarker testing.

Brandon Suh, CEO of Lunit, emphasized the pivotal role biomarker testing plays in precision oncology. He noted, "Biomarker testing is at the heart of precision oncology, but today it is still largely dependent on manual interpretation." By combining forces with Agilent, Lunit aims to accelerate the market entry of biomarker-driven therapies, ensuring that patients receive timely and appropriate treatments.

Nina Green, Vice President and General Manager of Agilent's Clinical Diagnostics Division, reiterated the importance of this partnership: "Agilent is committed to bringing cutting-edge diagnostic solutions to our pharmaceutical partners and ultimately to patients. This collaboration with Lunit further strengthens our ability to offer the most advanced companion diagnostic solutions available today."

The collaboration will commence with the co-development of AI-powered assays that can be utilized in both research and clinical trial settings. This marks a significant advancement for both companies as they collectively seek to redefine the role of artificial intelligence in precision oncology and translational medicine.

About Lunit

Founded in 2013, Lunit has quickly established itself as a global leader in AI for cancer diagnostics and therapeutics. With its mission to conquer cancer through artificial intelligence, the company has developed solutions aimed at enhancing medical imaging and biomarker analysis. Lunit's FDA-cleared Lunit INSIGHT suite is already in use for cancer screening across over 7,000 medical institutions worldwide. Furthermore, Lunit SCOPE is utilized in partnerships with major pharmaceutical companies focusing on biomarker development and companion diagnostics.

Lunit's groundbreaking clinical studies have been recognized in top-tier medical journals such as The Lancet Digital Health and the Journal of Clinical Oncology, as well as prominent medical conferences including ASCO and RSNA. Headquartered in Seoul, Lunit continues to innovate and drive the global fight against cancer. To learn more about Lunit’s commitment to AI in healthcare, visit lunit.io.

As Lunit and Agilent embark on this collaboration, the healthcare community eagerly anticipates the advancements and innovations that will emerge from their joint efforts, with the hope of delivering more effective and patient-centric treatment modalities in the near future.